TXMD News and Press, TherapeuticsMD Inc. From 04/21/21

Although sales grew by 30% in the fourth quarter, the market remains disinterested. ANNOVERA remains the key. Management are bullish on what is to come without restrictions in a post-covid world. The market remains concerned about dilution, negative earnings, and negative equity. ...

TXMD has a market disruptive product called ANNOVERA. However, uptake has not been satisfactory. The company has high debt and needs to cut expenses. For further details see: TherapeuticsMD: Great Product, But We Are Underwhelmed By Execution

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Castor Maritime (NASDAQ: CTRM ) stock got a boost on Friday after announcing the acquisition of a new shipping vessel. Source: VladSV / Shutterstock.com According to a news release , Castor Maritime has agree...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips TherapeuticsMD (NASDAQ: TXMD ) stock is up on Friday after announcing approval for one of its treatments in two parts of Europe. Source: Shutterstock Bijuve is the treatment behind today’s news . It&#x...

Celcuity (CELC) +55% on licensing agreement up to $340M for breast cancer treatment gedatolisib.Affimed N.V. (AFMD) +29% on positive data from NK cells + AFM13 in solid tumors.Greenwich LifeSciences (GLSI) +29% on robust immune response Phase IIb data in breast cancer.Gulf Reso...

An oral hormone replacement therapy marketed by TherapeuticsMD (TXMD) has been granted regulatory approval in the U.K. and Belgium. TherapeuticsMD shares have added ~11.4% in the pre-market.The Medicines and Healthcare products Regulatory Agency (“MHRA”) in the U....

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, and Theramex, a dedicated women’s health company, announced that BIJUVE ® has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for use in t...

The following slide deck was published by TherapeuticsMD, Inc. in conjunction with this event. For further details see: TherapeuticsMD (TXMD) Presents At H.C. Wainwright Global Life Sciences Conference

Evofem recently launched the first new non-hormonal birth control option in decades. Clinical efficacy falls short of the copper IUD, PARAGARD, but that device I believe may come with significant side effects. A trend in birth control centered on the woman's quality of life (safet...

The following slide deck was published by TherapeuticsMD, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: TherapeuticsMD, Inc. 2020 Q4 - Results - Earnings Call Presentation